Revolutionizing Medicine: How mRNA Technology Engineers Next-Generation Antibodies

By Christian Cobaugh, CEO and Founder

Monoclonal antibodies (mAbs) have revolutionized drug development and research tools due to their specificity and ease of production. Traditional methods involve immunizing animals with target antigens, but this can be costly and time-consuming. A promising alternative is lipid nanoparticle (LNP)-formulated mRNA encoding antigens.

Vernal Biosciences offers a unified mRNA manufacturing platform for rapid production of high-purity mRNA, enabling the creation of ready-to-immunize LNPs. These LNPs deliver mRNA to immune cells, facilitating antigen expression and inducing a robust immune response. This approach not only accelerates the immunization process but also yields high-quality antibodies with improved glycoforms and protein structures. Vernal’s formulations ensure high sera titers, making them suitable for various administration routes.

With the potential to revolutionize antibody discovery, mRNA-encoded antigens represent a significant advancement in the field. Learn more about the full potential of this technology by accessing the full article below.